{
    "cancer_info": {
        "cancer_name": "Gestational Trophoblastic Neoplasia (GTN)"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Pelvic exam (avoid biopsy of lower genital tract lesions)",
            "Quantitative serum hCG assay with dilution studies",
            "Complete blood count (CBC)",
            "Liver function tests",
            "Renal function tests",
            "Thyroid function tests",
            "Blood type and screen",
            "Rho(D) immunoglobulin administration for Rh-negative patients",
            "Pelvic ultrasound",
            "Chest X-ray",
            "C/A/P CT with contrast (if metastases suspected)",
            "Brain MRI with/without contrast",
            "Pelvic MRI",
            "FDG PET-CT (for metastasis detection/surgical targeting)",
            "Histopathology (IHC markers: Mel-CAM, hPL, β-hCG, p63, cyclin E)",
            "DNA genotyping (for hydatidiform mole classification)",
            "Repeat imaging for persistent/resistant disease"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Hydatidiform Mole (HM)",
            "risk_group": "All",
            "treatment_plans": [
                {
                    "treatment_line": "Initial treatment",
                    "patient_subgroup": "All patients",
                    "plan_name": "Suction D&C",
                    "plan_details": "Ultrasound-guided suction dilation and curettage ± uterotonics (e.g., oxytocin)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Prophylactic chemotherapy",
                    "patient_subgroup": "High-risk HM",
                    "plan_name": "Methotrexate/Dactinomycin",
                    "plan_details": "Consider for high-risk HM (risk factors: Age>40, hCG>100,000 mIU/mL)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Consideration"
                },
                {
                    "treatment_line": "Persistent disease",
                    "patient_subgroup": "No metastases",
                    "plan_name": "Single-agent chemotherapy",
                    "plan_details": "Methotrexate (0.4 mg/kg IV/IM ×5d q14d) or Dactinomycin (0.5 mg IV ×5d q14d)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Resistant disease",
                    "patient_subgroup": "Multiagent resistance",
                    "plan_name": "EMA-CO",
                    "plan_details": "Multiagent chemotherapy regimen",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Surgical option",
                    "patient_subgroup": "Fertility not desired",
                    "plan_name": "Hysterectomy",
                    "plan_details": "Hysterectomy for resistant disease",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Option"
                }
            ]
        },
        {
            "staging_criteria": "Any FIGO stage with low risk score (≤6)",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "All low-risk GTN",
                    "plan_name": "Methotrexate/Dactinomycin",
                    "plan_details": "Methotrexate (0.4 mg/kg IV/IM daily ×5d q14d) or Dactinomycin (0.5 mg IV daily ×5d q14d or 1.25 mg/m² IV pulse q14d)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Response management",
                    "patient_subgroup": "hCG normalization",
                    "plan_details": "Continue 2-3 cycles past normalization",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard"
                },
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "hCG >1,000 or resistance",
                    "plan_name": "EMA-CO",
                    "plan_details": "Multiagent chemotherapy regimen",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Any FIGO stage with high risk score (≥7)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "All high-risk GTN",
                    "plan_name": "EMA-CO",
                    "plan_details": "Multiagent chemotherapy ± etoposide/cisplatin induction for extensive metastases",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "CNS metastases",
                    "patient_subgroup": "Brain metastases",
                    "plan_name": "High-dose methotrexate",
                    "plan_details": "Methotrexate 1,000 mg/m² + leucovorin rescue ± whole-brain RT (30 Gy/15 fx) or SBRT/craniotomy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Salvage therapy",
                    "patient_subgroup": "Resistant disease",
                    "plan_name": "Multiagent regimens",
                    "plan_details": "EMA-EP, EP-EMA, TP-TE, BEP, VIP, ICE, TIP",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended regimen"
                },
                {
                    "treatment_line": "Immunotherapy",
                    "patient_subgroup": "Multiagent-resistant GTN",
                    "plan_name": "PD-1/PD-L1 inhibitors",
                    "plan_details": "Pembrolizumab, nivolumab ± ipilimumab, avelumab",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred for resistant GTN"
                }
            ]
        },
        {
            "staging_criteria": "Stage I (PSTT/ETT)",
            "risk_group": "Without poor prognostic factors",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Non-metastatic",
                    "plan_name": "Hysterectomy + salpingectomy",
                    "plan_details": "Hysterectomy with bilateral salpingectomy ± pelvic lymph node biopsy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage I (PSTT/ETT)",
            "risk_group": "With poor prognostic factors",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "High-risk features (interval ≥4 yr, deep invasion, etc.)",
                    "plan_name": "Surgery + chemotherapy",
                    "plan_details": "Hysterectomy/salpingectomy followed by platinum-based chemo (EMA-EP, BEP, VIP)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage II-IV (PSTT/ETT)",
            "risk_group": "Metastatic",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Metastatic disease",
                    "plan_name": "Platinum-based chemotherapy",
                    "plan_details": "EMA-EP, EP-EMA, TP/TE ± metastasectomy for isolated lesions",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Salvage therapy",
                    "patient_subgroup": "Resistant disease",
                    "plan_name": "Immunotherapy/targeted agents",
                    "plan_details": "PD-1 inhibitors (nivolumab/pembrolizumab), capecitabine, gemcitabine",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Useful in certain circumstances"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "hCG: Primary tumor marker for diagnosis/monitoring (except PSTT/ETT); persistent elevation (plateau over 4 values/3wk or rise over 3 values/2wk) defines GTN; quiescent GTN indicated by low/stable hCG without disease evidence",
            "IHC markers: Differentiate subtypes - Choriocarcinoma (high β-hCG, low hPL), PSTT (high hPL, diffuse Mel-CAM), ETT (high p63, weak Mel-CAM/hPL)",
            "PD-L1 expression: Predicts response to PD-1/PD-L1 inhibitors (pembrolizumab/nivolumab/avelumab)",
            "Tumor-Infiltrating Lymphocytes (TILs): Absence associated with pembrolizumab resistance despite PD-L1 positivity",
            "Genetic testing: DNA genotyping confirms hydatidiform mole type (complete: diploid diandric; partial: triploid)"
        ]
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：妊娠滋养细胞肿瘤.txt"
}